Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propanediolo monoidrato - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - farmaci usati nel diabete - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. in aggiunta ad altri medicinali per il trattamento del diabete di tipo 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Unione Europea - italiano - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - sclerosi multipla - immunosoppressori selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leucemia, hairy cell - agenti antineoplastici - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Unione Europea - italiano - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - infezioni da cytomegalovirus - antivirali per uso sistemico - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antivirali.

Unione Europea - italiano - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mieloma multiplo - agenti antineoplastici - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Unione Europea - italiano - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mieloma multiplo - agenti antineoplastici - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mieloma multiplo - agenti antineoplastici - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - mieloma multiplo - agenti antineoplastici - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

theramex ireland limited - levonorgestrel ed estrogeno - levonorgestrel ed estrogeno

Unione Europea - italiano - EMA (European Medicines Agency)

dany bienenwohl gmbh - l'acido ossalico diidrato - ectoparassiticidi per uso topico, incl. insetticidi - api - per il trattamento di varroosis (varroa destructor) per le api da miele (apis mellifera) in brood-gratis colonie.